Comments: No Comments
September 7th, 2018, Stuart, Florida
For Immediate Release
Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced today that it has been selected to present as one of a handful of emerging companies at the Next Generation Session during the 24th annual BIO-Europe Conference, November 5 -7, 2018, in Copenhagen, Denmark. BIO-Europe is the largest life science partnering conference in Europe.
Stuart Therapeutics’ presentation will focus on the notable pre-clinical results that the company has generated for its collagen mimetic polypeptide, PolyCol™, and its plans for further development and FDA approval as a therapy for dry eye disease and other ocular surface conditions.
PolyCol is a patented polypeptide that mimics human collagen. PolyCol targets, anchors to and repairs damaged collagen in the body, and can also deliver a chemically linked therapeutic, making it an ideal combination therapy for a variety of clinical conditions. Stuart is developing its first product, ST-100, as a drop formulation for dry eye disease, to repair damage to the ocular surface caused by dry eye, providing rapid relief of signs and symptoms of the indication. Stuart believes that PolyCol will be broadly applicable to the estimated 30 million sufferers of dry eye disease in the United States, due to its direct reparative approach to painful damage to the surface of the eye.
“Stuart Therapeutics is pleased to have been selected to present at BIO-Europe,” said Eric Schlumpf, President and CEO of Stuart Therapeutics, Inc. “We look forward to sharing our compelling results, and actively engaging with potential strategic partners and prospective investors at the conference.”
About Stuart Therapeutics:
Stuart Therapeutics is a pre-clinical stage pharmaceutical company focused on the development of PolyCol, a collagen mimetic peptide therapeutic platform. The company is developing ophthalmologic and other applications for this technology.
ST-100 is a candidate therapeutic that is in pre-clinical evaluation and has not been approved by the U.S. Food and Drug Administration (FDA) for use in treating, preventing, curing or diagnosing any disease or disorder. Similarly, the statements contained in this Announcement have not been evaluated by the FDA, and may be considered “forward-looking statements” under applicable securities laws. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of Stuart Therapeutics believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Stuart Therapeutics undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Stuart Therapeutics, Inc.